Fulgent's Solid Tumor Molecular Profile targets 170 cancer-related genes carefully selected to provide comprehensive and efficient analysis of therapeutically relevant alterations as well as those being studied in current and upcoming clinical trials. Our expert curation team creates each report considering the mutational status of all tested genes, resulting in a personalized profile including recommendations for approved therapies, counter-indicated therapies, off-label options, and active trials. With this powerful tool in hand, patients and care teams are armed with the best information possible to navigate the increasingly complex battle against cancer.